Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002814 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy for Patients With Brain Cancer

A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT00002814: Completed Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Dartmouth-Hitchcock Medical Center.

NCT00002814 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 20 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002814, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy using paclitaxel and topotecan, plus G-CSF, in treating patients with glioblastoma multiforme or anaplastic astrocytoma that is refractory or recurrent.

Interventions

  • DRUG paclitaxel
  • BIOLOGICAL filgrastim
  • DRUG topotecan hydrochloride

Study Locations (1)

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1996-08
Est. Completion 2001-12
Phase Phase 2
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT00002814 record still lists

NCT00002814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which paclitaxel is the first listed.

NCT00002814 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT00002814 about?

NCT00002814 is a clinical study titled "Combination Chemotherapy for Patients With Brain Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy using paclitaxel and topotecan, plus G-CSF, ...

What is the current status of trial NCT00002814?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1996-08. Estimated completion is 2001-12.

What conditions does trial NCT00002814 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00002814?

The interventions under investigation include: paclitaxel (DRUG), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002814?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002814 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002814's enrollment target sits among peer trials

20 36th of 45 higher than 9 of 45 other Brain and Central Nervous System Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002814, the US trial registry maintained by the National Library of Medicine. NCT00002814 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.